Form 4: Elanco CEO Acquires Deferred Stock Units

Elanco Animal Health CEO Jeffrey N. Simmons acquired 130.0723 deferred stock units, increasing his beneficial ownership in the company.

Summary

• Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc (ELAN), acquired 130.0723 Deferred Stock Units (DSUs).
• The transaction occurred on December 12, 2025.
• Each DSU represents the right to receive one share of Company common stock or its cash equivalent.
• The DSUs were acquired at a price of $21.29 per unit.
• Following this transaction, Mr. Simmons beneficially owns 18,604.9984 derivative securities.
• These DSUs settle in cash or shares upon termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Sentiment

Score: 7

Explanation: The acquisition of deferred stock units by the CEO is generally viewed as a positive signal, indicating management's continued alignment with shareholder interests and confidence in the company's long-term prospects. However, the relatively small size of the acquisition limits its overall impact on sentiment.

Positives

• An insider, the President, CEO, and Director, increased their beneficial ownership in the company, which can signal confidence in future performance.
• The acquisition of deferred stock units aligns management's interests with long-term shareholder value.

Negatives

• No direct negatives are apparent from this routine insider transaction filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction and does not provide specific information to analyze broader industry trends or competitor actions. It reflects an individual executive's compensation and ownership changes within the animal health sector.

Comparison to Industry Standards

• This filing is a standard insider transaction report (Form 4) and does not contain information suitable for comparison to global benchmarks, specific comparable companies, projects, or results.

Stakeholder Impact

• Shareholders: Potentially positive, as increased insider ownership can signal confidence and align management interests with long-term shareholder value.
• Employees, Customers, Suppliers, Creditors: No direct or immediate impact is indicated by this filing.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing.

Key Dates

Keywords

Elanco Animal Health, ELAN, Jeffrey N. Simmons, Insider Transaction, Form 4, Deferred Stock Units, CEO, Stock Ownership